AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05413239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation to reduce diabetes distress and improve glycemic outcomes
Description: The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting \~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
Study NCT05504850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multicultural Health Diet
Description: The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
Study NCT05215275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds.
Study NCT05716893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Aerobic Training/AT Dosing
Description: o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
Study NCT05716893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard (fixed) Aerobic Training/AT dosing
Description: In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
Study NCT04812002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor， bevacizumab
Description: Both drugs are given intravenously
Study NCT06268067 — intervention group
Intervention type: DEVICE
Intervention: PET/CT
Description: F-18 FDG PET/CT studies
Study NCT06584110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buddy-Up Dyadic Physical Activity (BUDPA) program
Description: BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support.
Study NCT06584110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care with waiting list
Description: Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
Study NCT06020183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid hyrax
Description: these patents will be treated using Four mini-screws supported hybrid hyrax
Study NCT04616729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 MG Injection
Description: Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.
Study NCT04616729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal oocyte retrieval
Description: Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
Study NCT04616729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal oocyte retrieval
Description: Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
Study NCT04616729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Injection
Description: Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
Study NCT05133973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense CGM
Description: FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
Study NCT05008939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
Study NCT05008939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received 30% oxygen for 1 hour.
Study NCT05008939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients received 30% oxygen for 1 hour.
Study NCT05901064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary clearance
Description: Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
Study NCT04614168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepped hyperinsulinaemic-hypoglycaemic clamp study
Description: Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
Study NCT04614168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stepped hyperinsulinaemic-hypoglycaemic clamp study
Description: Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
Study NCT04614168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
Study NCT04614168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
Study NCT04614168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: 30-40g of carbohydrate per main meal portion.
Study NCT04614168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blinded continuous glucose monitor
Description: Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
Study NCT04614168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blinded continuous glucose monitor
Description: Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
Study NCT04614168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stable isotope studies- D2 Glucose and D5 Glycerol
Description: These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
Study NCT04614168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable isotope studies- D2 Glucose and D5 Glycerol
Description: These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
Study NCT05082961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples
Description: Samples to evaluate the circulating CD8+ T cell count.
Study NCT06211322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urika, a self-management application for patients with gout
Description: The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
Study NCT06260397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus anterior plane block
Description: using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles
Study NCT06260397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: costotransverse block
Description: using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib
Study NCT06260397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient controlled analgesia
Description: PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
Study NCT06520124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essilor® Stellest® spectacle lens
Description: Spectacle lens with highly aspherical lenslets.
Study NCT06520124 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-vision spectacle lens
Description: Standard single-vision distance spectacle lens.
Study NCT04092010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving education (PSE)
Description: PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
Study NCT04092010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement sessions
Description: Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
Study NCT04092010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Normal services provided children and their mothers in Head Start
Study NCT05269966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection Brolucizumab
Description: Single-chain antibody fragment (scFv)~Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing.
Study NCT06444074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Activation through Conversations (PACT) Program
Description: Participants in the intervention arm will undergo a 3-month long health coaching program where a care coach will review a participant's health parameters and current self-care behaviours, identify health motivators and set goals for improving their diabetes, as well as fortnightly support through text or phone call.
Study NCT06444074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Routine Chronic Disease care
Study NCT05983952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 antibody Injection
Description: intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Ten subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment.
Study NCT04754997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercise training
Description: The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
Study NCT04754997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercise training
Description: The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
Study NCT06131450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study NCT05833126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
Description: Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
Study NCT06355661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule
Description: Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
Study NCT06355661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MCC: 400 mg (± 10%) per Capsule
Description: Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
Study NCT05756881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cosmetic product
Description: Apply on the face twice a day
Study NCT05756881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cosmetic product
Description: Apply on the face twice a day
Study NCT05434455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion
Description: RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
Study NCT05052853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
Study NCT05052853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study NCT06524986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy promoting program using computer game
Description: The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes. Activities include: 1) Enactive Mastery Experiences 2) Modeling 3) Verbal Persuasion 4) Physiological and Affective States Assessment
Study NCT06524986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard nursing care
Description: The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
Study NCT05337865 — intervention group
Intervention type: OTHER
Intervention: Aerobic exercise test.
Description: Aerobic exercise test at a treadmill.
Study NCT05668897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Study NCT05668897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of GST-HG171
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Study NCT05863819 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.
Study NCT05801003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predilation with cutting balloon.
Description: PCI will be performed under OCT guidance. Predilation of the lesion will be done with cutting balloon.
Study NCT05801003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predilation with conventional balloon
Description: PCI will be performed under OCT guidance. Predilation of the lesion will be done with conventional balloon (semi-compliant or non-compliant)
Study NCT06533085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block by surgeon
Description: Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)
Study NCT05172050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.
Study NCT05172050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)
Study NCT06487104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrachPhone HME
Description: Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients.